Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Policy / Regulatory

NHSA to Announce NRDL Adjustment Results at November 28th Press Conference

Fineline Cube Nov 26, 2024

The National Healthcare Security Administration (NHSA) will unveil the results of the negotiation and price...

Policy / Regulatory

NMPA and Local Governments Streamline Drug Approval Processes in China

Fineline Cube Nov 26, 2024

The National Medical Products Administration (NMPA) has released a notification regarding the pilot work for...

Company Deals

Adcendo ApS Secures Oversubscribed USD135 Million Series B Financing to Advance ADC Pipeline

Fineline Cube Nov 26, 2024

Danish antibody drug conjugate (ADC) specialist, Adcendo ApS, has announced the completion of an oversubscribed...

Company Medical Device

Abbott Laboratories Expands Structural Heart Portfolio with TAVI Balloon-Expandable System

Fineline Cube Nov 26, 2024

US-based Abbott Laboratories (NYSE: ABT) has announced the successful application of its transcatheter aortic valve...

Company Drug

Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH

Fineline Cube Nov 26, 2024

US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced positive interim analysis results...

Company Deals

Boston Scientific Corporation to Acquire Intera Oncology Inc., Expanding Cancer Treatment Portfolio

Fineline Cube Nov 26, 2024

US-based medical device giant Boston Scientific Corporation (NYSE: BSX) has announced a definitive acquisition agreement...

Company Drug

Nasal-Phyto Pharmaceutical Receives FDA Clearance for First-Ever Olfactory Drug-Device Combo

Fineline Cube Nov 26, 2024

China-based Nasal-Phyto Pharmaceutical Technology Group Co., Ltd has announced receiving clinical clearance from the US...

Company Drug

GSK’s Blenrep BLA for Multiple Myeloma Treatments Accepted by FDA for Review

Fineline Cube Nov 26, 2024

UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that the US Food and Drug...

Company Drug

Insilico Medicine Gets FDA Approval for Clinical Study of ENPP1 Inhibitor ISM5939

Fineline Cube Nov 26, 2024

China’s generative artificial intelligence (AI)-driven biotech company, Insilico Medicine, has announced that it has received...

Company Drug

SCG Cell Therapy Presents Phase I Data for HBV-Specific TCR-T Therapy SCG101 at AASLD 2024

Fineline Cube Nov 26, 2024

SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has announced...

Company Drug

Shenzhen Kangtai Begins Phase I Clinical Trial for 20-Valent Pneumococcal Vaccine

Fineline Cube Nov 26, 2024

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the enrollment of the...

Company Drug

Sichuan Kelun-Biotech Receives NMPA Clearance for SKB501 Clinical Trial in Solid Tumors

Fineline Cube Nov 26, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from...

Company Drug

Lepu Medical Technology Gains NMPA Approval for Obesity and Diabetes Treatments MWN109 and MWN105

Fineline Cube Nov 26, 2024

China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease...

Company Deals

3SBio Inc. Secures Licensing Deal with Sunshine Lake Pharma for Clifutinib Commercialization

Fineline Cube Nov 26, 2024

China-based 3SBio Inc. (HKG: 1530) has announced a licensing deal with fellow Chinese firm Sunshine...

Company Drug

Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH

Fineline Cube Nov 26, 2024

US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced favorable interim analysis results...

Company Deals

Hubei Guangji Pharmaceutical Expands Ex-Hospital Market Presence with New Partnerships

Fineline Cube Nov 26, 2024

China-based Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) is poised to establish a strong presence...

Company Drug

GeneQuantum Healthcare’s GQ1011 (AMB302) Receives FDA Approval for Clinical Study

Fineline Cube Nov 26, 2024

China-based GeneQuantum Healthcare, a leading developer of antibody drug conjugates (ADCs), has announced that it...

Company Deals

E-nitiate Biopharmaceuticals Strikes Licensing Deal with Joincare for QY101 Inhaler Rights

Fineline Cube Nov 26, 2024

China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a joint venture between VivaVision Biotech and Betta Pharmaceuticals...

Company Deals

Luye Pharma’s Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil

Fineline Cube Nov 25, 2024

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955),...

Company Deals

Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million

Fineline Cube Nov 25, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced revisions to its private placement plan,...

Posts pagination

1 … 283 284 285 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.